These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26916894)

  • 21. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of TP53 mutations, codon 72 polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients.
    Shi Q; Xiao K; Wei W; Zhang BY; Chen C; Xu Y; Chen LN; Song YT; Ma X; Zhang NS; Dong XP
    Oncol Rep; 2013 Dec; 30(6):2811-9. PubMed ID: 24064928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
    Borchiellini D; Etienne-Grimaldi MC; Bensadoun RJ; Benezery K; Dassonville O; Poissonnet G; Llorca L; Ebran N; Formento P; Château Y; Thariat J; Milano G
    Oral Oncol; 2017 Apr; 67():70-76. PubMed ID: 28351583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
    Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
    J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
    Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
    Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection.
    Li J; Tang Y; Huang L; Yu Q; Hu G; Yuan X
    PLoS One; 2016; 11(7):e0158613. PubMed ID: 27414035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.
    Jin L; Sturgis EM; Zhang Y; Huang Z; Wei P; Guo W; Wang Z; Wei Q; Song X; Li G
    Carcinogenesis; 2013 Jul; 34(7):1551-7. PubMed ID: 23508638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
    Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
    Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
    PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
    Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
    Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
    Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
    Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.
    Zawlik I; Kita D; Vaccarella S; Mittelbronn M; Franceschi S; Ohgaki H
    Brain Pathol; 2009 Apr; 19(2):188-94. PubMed ID: 18462472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
    Patel H; Polanco-Echeverry G; Segditsas S; Volikos E; McCart A; Lai C; Guenther T; Zaitoun A; Sieber O; Ilyas M; Northover J; Silver A
    Int J Cancer; 2007 Dec; 121(12):2668-73. PubMed ID: 17721920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.
    Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH
    Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
    Zhou G; Liu Z; Myers JN
    J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
    Tantengco OAG; Nakura Y; Yoshimura M; Llamas-Clark EF; Yanagihara I
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2103-2107. PubMed ID: 31350972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.